Exelixis, an oncology company based in Alameda, California, focuses on developing treatments for difficult-to-treat cancers, with four marketed products including cabozantinib for various cancers. Founded in 2000, it employs 1,310 people.
EXEL has been in the news recently: Exelixis, Inc. reported topline results from the STELLAR-303 trial, demonstrating the efficacy of zanzalintinib combined with atezolizumab in a phase 3 study. Additionally, analysts have expressed mixed opinions on Exelixis, with views ranging from bullish to bearish in recent evaluations.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
